Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 20;4(5):713-716.
doi: 10.1016/j.jaccao.2022.09.002. eCollection 2022 Dec.

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD

Daniel Oren  1 , Ersilia M DeFilippis  1 , Dor Lotan  1 , Kevin J Clerkin  1 , Justin Fried  1 , Ran Reshef  2 , Hilda Fernandez  3 , Edward Lin  1 , Jennifer Amengual  4 , Gabriel Sayer  1 , Nir Uriel  1 , Jayant K Raikhelkar  1
Affiliations
Review

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD

Daniel Oren et al. JACC CardioOncol. .
No abstract available

Keywords: CAR T cell; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; EBV, Epstein-Barr virus; PTLD, post-transplant lymphoproliferative disorder; heart transplantation; immunotherapy; kidney transplantation; post-transplant lymphoproliferative disorder.

PubMed Disclaimer

Conflict of interest statement

Dr Clerkin was supported by National Institutes of Health grant K23 HL148528. Dr Reshef has served as a consultant or advisor for Atara Biotherapeutics, Gilead Sciences, Novartis, Bristol-Myers Squibb, Regeneron, TScan, Synthekine, and Jasper; served as an expert witness for Bayer; and received research funding from Atara Biotherapeutics, Incyte, CareDx, Pharmacyclics, Shire, Immatics, Takeda, Gilead Sciences, J&J, and Precision Biosciences. Dr Sayer has served as a consultant for Medtronic. Dr Uriel has received grant support from Abbott and CareDx. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
CAR T Cell Therapy for PTLD Flow chart depicting the development of post-transplant lymphoproliferative disorder (PTLD) following immunosuppressive therapy, percurrent of T cells followed by generation of chimeric antigen receptor (CAR) T cells, clone expansion, and infusion with subsequent binding of CAR T cells to cancer cells. Illustration generated using BioRender.
See this image and copyright information in PMC

References

    1. Peters A.C., Akinwumi M., Cervera C., et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years. Transplantation. 2018;102(9):1553–1562. doi: 10.1097/TP.0000000000002146. - DOI - PubMed
    1. Youn J.C., Stehlik J., Wilk A.R., et al. Temporal trends of de novo malignancy development after heart transplantation. J Am Coll Cardiol. 2018;71(1):40–49. doi: 10.1016/j.jacc.2017.10.077. - DOI - PubMed
    1. Trappe R.U., Dierickx D., Zimmermann H., et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35(5):536–543. doi: 10.1200/jco.2016.69.3564. - DOI - PubMed
    1. Nastoupil L.J., Jain M.D., Feng L., et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119–3128. doi: 10.1200/jco.19.02104. - DOI - PMC - PubMed
    1. Daud A., Mehra M.R., Siu A., et al. Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative. J Heart Lung Transplant. 2020;39(6):604–606. doi: 10.1016/j.healun.2020.02.015. - DOI - PubMed

LinkOut - more resources